FebriDx DISRUPT Acute Respiratory Infection Trial in Acute Respiratory Infection: An Evaluation of FebriDx® POC Test

CompletedOBSERVATIONAL
Enrollment

540

Participants

Timeline

Start Date

October 15, 2019

Primary Completion Date

April 30, 2021

Study Completion Date

June 10, 2021

Conditions
Acute Respiratory Tract Infections
Interventions
DIAGNOSTIC_TEST

FebriDx

Point of Care Host Immune Response Test

Trial Locations (20)

11215

New York Methodist Hospital, Brooklyn

29607

Parkside Pediatrics, Greenville

29611

Woodruff Road Urgent Care Center, P.C./ Urgent Care Clinical Trials, Greenville

29640

Woodruff Road Urgent Care Center/Urgent Care Clinical Trials, Easley

33016

Doral Medical Research, Hialeah

33134

Clinical Research of South Florida, Coral Gables

33613

PAS Research, Tampa

37203

Clinical Research Associates, Nashville

37232

VA Office of Research and Development/Vanderbilt University School of Medicine, Nashville

37421

AFC Urgent Care/Urgent Care Clinical Trials, Chattanooga

53226

Medical College of Wisconsin, Milwaukee

53705

University of Wisconsin-Madison/Berbee Walsh Department of Emergency Medicine, Madison

75204

Urgent Care Clinical Trials, Dallas

76904

Benchmark Research, San Angelo

80246

AFC Urgent Care/Urgent Care Clinical Trials, Denver

35294-0111

University of Alabama, Birmingham

02114

Massachusetts General, Boston

02115

Brigham & Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

01608

St. Vincent Hospital, Worcester

All Listed Sponsors
lead

Rapid Pathogen Screening

INDUSTRY

NCT02018198 - FebriDx DISRUPT Acute Respiratory Infection Trial in Acute Respiratory Infection: An Evaluation of FebriDx® POC Test | Biotech Hunter | Biotech Hunter